BR0317349A - Droga sólida para uso oral - Google Patents

Droga sólida para uso oral

Info

Publication number
BR0317349A
BR0317349A BR0317349-6A BR0317349A BR0317349A BR 0317349 A BR0317349 A BR 0317349A BR 0317349 A BR0317349 A BR 0317349A BR 0317349 A BR0317349 A BR 0317349A
Authority
BR
Brazil
Prior art keywords
solid drug
oral use
pharmaceutically acceptable
elution
prodrug
Prior art date
Application number
BR0317349-6A
Other languages
English (en)
Inventor
Tsuyoshi Naganuma
Mitsuo Muramatsu
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32588229&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0317349(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of BR0317349A publication Critical patent/BR0317349A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"DROGA SóLIDA PARA USO ORAL". A presente invenção pretende proporcionar uma droga sólida para ser usada por via oral para o tratamento de distúrbios urinários que contenham um composto de indolina dotado de um efeito de bloqueio de receptor <244>1-adrenérgico, e sendo representado pela fórmula a seguir; a sua prodroga, um sal farmaceuticamente aceitável do mesmo ou um solvato farmaceuticamente aceitável do mesmo, e é preparada de modo a apresentar um tempo de elução de 85% não superior a 60 minutos no teste de elução em água, de acordo com o segundo método de teste de elução (o método de espátula) na Farmacopéia Japonesa.
BR0317349-6A 2002-12-16 2003-12-11 Droga sólida para uso oral BR0317349A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002364238 2002-12-16
PCT/JP2003/015837 WO2004054574A1 (ja) 2002-12-16 2003-12-11 経口固形医薬

Publications (1)

Publication Number Publication Date
BR0317349A true BR0317349A (pt) 2005-11-16

Family

ID=32588229

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317349-6A BR0317349A (pt) 2002-12-16 2003-12-11 Droga sólida para uso oral

Country Status (24)

Country Link
US (2) US20060018959A1 (pt)
EP (2) EP2402010A1 (pt)
JP (1) JP4633469B2 (pt)
KR (2) KR101072909B1 (pt)
CN (2) CN100339078C (pt)
AU (1) AU2003289320C1 (pt)
BR (1) BR0317349A (pt)
CA (1) CA2507002C (pt)
EA (1) EA008196B1 (pt)
ES (1) ES2544560T3 (pt)
HK (2) HK1085131A1 (pt)
HR (1) HRP20050544B1 (pt)
IL (1) IL169040A (pt)
IS (1) IS7929A (pt)
ME (2) ME00076B (pt)
MX (1) MXPA05006513A (pt)
NO (1) NO20053467L (pt)
NZ (1) NZ540664A (pt)
PL (1) PL220457B1 (pt)
RS (1) RS58025B1 (pt)
TW (2) TWI325318B (pt)
UA (2) UA84694C2 (pt)
WO (1) WO2004054574A1 (pt)
ZA (1) ZA200504613B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2436608T3 (es) * 2004-03-05 2014-01-03 Kissei Pharmaceutical Co., Ltd. Composición medicinal para la prevención o el tratamiento de la vejiga hiperactiva asociada a un trastorno nervioso
CA2582339C (en) * 2004-10-05 2014-04-22 Kissei Pharmaceutical Co., Ltd. Preventive and/or therapeutic agent for a storage disorder accompanying benign prostatic hyperplasia
MX2009009230A (es) * 2007-02-28 2009-11-26 Kissei Pharmaceutical Uso de silodosina en una administracion diaria para tratar hiperplasia prostatica benigna.
EP2120885A2 (en) * 2007-03-13 2009-11-25 Takeda Pharmaceutical Company Limited Solid preparation comprising 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-4-fluorobenzonitrile
WO2012000926A1 (de) 2010-06-28 2012-01-05 Ratiopharm Gmbh Silodosin-cyclodextrin einschlussverbindungen
EP2595607A2 (de) 2010-07-23 2013-05-29 Ratiopharm GmbH Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer
PL2474529T3 (pl) 2010-12-23 2014-10-31 Sandoz Ag Formy krystaliczne farmaceutycznej substancji czynnej
CN102283816B (zh) * 2011-08-05 2013-09-11 北京海步国际医药科技发展有限公司 西洛多辛缓释片剂及其制备方法
US20140243383A1 (en) * 2011-08-24 2014-08-28 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
JP6031722B2 (ja) * 2011-08-31 2016-11-24 国立大学法人 千葉大学 女性の排尿障害の治療剤
MX2014009889A (es) * 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
RS57795B1 (sr) 2012-07-16 2018-12-31 Fibrogen Inc Kristalni oblici inhibitora prolil hidroksilaze
CN105142633A (zh) 2013-03-26 2015-12-09 橘生药品工业株式会社 西洛多辛苦味被掩蔽的口服给药制剂
CN111728952A (zh) 2013-06-06 2020-10-02 菲布罗根有限公司 Hif羟化酶抑制剂的药物制剂
KR102206104B1 (ko) * 2014-04-03 2021-01-22 한미약품 주식회사 실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형
CN103933001A (zh) * 2014-05-09 2014-07-23 浙江华海药业股份有限公司 一种稳定的赛洛多辛口服固体药物组合物及其制备方法
CN105435233B (zh) * 2014-08-06 2018-05-01 江苏正大丰海制药有限公司 一种英加韦林的药物组合物
JP6366547B2 (ja) * 2015-08-03 2018-08-01 大原薬品工業株式会社 光安定性が向上した、プラミペキソール製剤包装体
CN108685867A (zh) * 2017-04-06 2018-10-23 昆明积大制药股份有限公司 一种赛洛多辛薄膜衣片及其制备方法
EP3354283B1 (en) 2017-06-20 2019-08-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical capsule composition comprising silodosin
CN111437260A (zh) * 2019-01-17 2020-07-24 北京万全德众医药生物技术有限公司 用于制备盐酸美金刚固态药物组合物的方法
JP7262005B2 (ja) * 2019-01-25 2023-04-21 日本ジェネリック株式会社 シロドシン含有固形組成物及びその製造法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060073A (en) 1963-03-02 1967-02-22 Benger Lab Ltd 2,2,2-trichlorethyl hydrogen succinate and salts
US4547498A (en) 1983-01-06 1985-10-15 Mylan Pharmaceuticals Inc. Pharmaceutical combination composition and associated method
US4757090A (en) * 1986-07-14 1988-07-12 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
HU200926B (en) * 1988-10-28 1990-09-28 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules
DE122010000031I1 (de) 1992-12-02 2010-10-21 Kissei Pharmaceutical Indolin Verbindungen zur Behandlung von Dysurien
US5370878A (en) * 1993-09-30 1994-12-06 Hallmark Pharmaceuticals, Inc. Method for preparing a direct compression granulated acetaminophen composition
US6068859A (en) 1994-05-06 2000-05-30 Pfizer Inc. Controlled-release dosage forms of Azithromycin
ES2125198B1 (es) * 1997-05-13 1999-11-16 Vita Invest Sa Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
AU9095998A (en) * 1997-09-22 1999-04-12 Kissei Pharmaceutical Co. Ltd. Remedies for dysuria resulting from prostatic hypertrophy
US20020177593A1 (en) * 1998-09-30 2002-11-28 Yuji Ishihara Agents and crystals for improving excretory potency of urinary bladder
JP4324266B2 (ja) * 1999-02-26 2009-09-02 キッセイ薬品工業株式会社 α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
US20010053780A1 (en) 1999-04-30 2001-12-20 Whitaker John S. Daily treatment for erectile dysfunction using a PDE5 inhibitor
JP4014068B2 (ja) * 1999-07-28 2007-11-28 芦森工業株式会社 エアバッグ装置
PE20011178A1 (es) * 2000-04-07 2001-11-19 Takeda Chemical Industries Ltd Compuestos heterociclicos y su produccion
EP1293206A4 (en) 2000-05-15 2005-09-21 Kissei Pharmaceutical LIQUID PREPARATION BASED ON WATER
DE60216890T2 (de) * 2001-01-26 2007-08-30 Schering Corp. Kombinationen von einem hemmer der sterol-absorption und einem ppar-aktivator zur behandlung von kardiovaskulären indikationen
JP2001288115A (ja) 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
US7189412B2 (en) * 2001-03-01 2007-03-13 Aska Pharmaceutical Co., Ltd. Fenofibrate-containing composition
US6786714B2 (en) * 2001-04-12 2004-09-07 James W. Haskew Delivery system for liquid catalysts
GB0113843D0 (en) 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
UA78854C2 (en) * 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same

Also Published As

Publication number Publication date
EP2402010A1 (en) 2012-01-04
ES2544560T3 (es) 2015-09-01
IL169040A (en) 2013-04-30
US20060018959A1 (en) 2006-01-26
NZ540664A (en) 2007-09-28
PL377495A1 (pl) 2006-02-06
CN101069685A (zh) 2007-11-14
PL220457B1 (pl) 2015-10-30
AU2003289320B2 (en) 2008-08-21
NO20053467L (no) 2005-07-15
HRP20050544B1 (hr) 2017-12-01
IS7929A (is) 2005-07-01
US20120064154A1 (en) 2012-03-15
CA2507002A1 (en) 2004-07-01
ZA200504613B (en) 2006-08-30
JPWO2004054574A1 (ja) 2006-04-20
CA2507002C (en) 2012-09-18
EA200500985A1 (ru) 2005-12-29
CN100339078C (zh) 2007-09-26
MXPA05006513A (es) 2005-09-08
UA85359C2 (ru) 2009-01-12
EP1574215A1 (en) 2005-09-14
EP1574215A4 (en) 2009-07-01
RS20050470A (en) 2007-09-21
ME00076B (me) 2011-02-10
AU2003289320A1 (en) 2004-07-09
TW200944200A (en) 2009-11-01
HRP20050544A2 (en) 2006-09-30
CN1726028A (zh) 2006-01-25
AU2003289320C1 (en) 2018-09-06
WO2004054574A1 (ja) 2004-07-01
TW200418457A (en) 2004-10-01
JP4633469B2 (ja) 2011-02-16
TWI325318B (en) 2010-06-01
EA008196B1 (ru) 2007-04-27
RS58025B1 (sr) 2019-02-28
KR20100133024A (ko) 2010-12-20
MEP10808A (en) 2010-06-10
KR20050084316A (ko) 2005-08-26
CN101069685B (zh) 2011-12-14
UA84694C2 (ru) 2008-11-25
KR101072909B1 (ko) 2011-10-17
KR101077061B1 (ko) 2011-10-26
TWI382838B (zh) 2013-01-21
HK1107768A1 (en) 2008-04-18
EP1574215B1 (en) 2015-07-15
HK1085131A1 (en) 2006-08-18

Similar Documents

Publication Publication Date Title
BR0317349A (pt) Droga sólida para uso oral
ES2354417T3 (es) Nuevo uso de una clase de compuestos peptídicos para tratar alodinia u otros tipos diferentes de dolor crónico o fantasma.
BR0312948A (pt) Pramipexole em forma de dosagem uma vez ao dia
BRPI0108380A8 (pt) fórmulas de opióides agonistas resistentes à adulteração, método para diminuir o abuso de um opióide agonista numa fórmula de dosagem oral, método de preparação de uma fórmula de dosagem oral e método de tratamento da dor
BRPI0409417A (pt) método para usar um composto, composto, e, composição
BR0308816A (pt) Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas
ES8505519A1 (es) Un procedimiento para la preparacion de 14-fluoromorfinanos utiles como analgesicos, narcoticos y-o agentes anorexicos.
BR0317149A (pt) Métodos para uso de uma composição para bebidas
NO20076319L (no) Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav
BRPI0408256A (pt) composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
CA2318095A1 (en) Methods of treating tardive dyskinesia and other movement disorders
BRPI0411936A (pt) composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
BR9915111A (pt) Partìculas revestidas de ibuprofeno cristalinogranulado
JP2004509841A (ja) Ｃｏｐｄの処置のための医薬組成物
IS8096A (is) Notkun karbamasepínafleiða til að meðhöndla órósemi í sjúklingum er þjást af vitglöpum
BR9909872A (pt) uso de dexmedetomidina para uma unidade de sedação de proteção intensiva
BR0206237A (pt) Uso de um composto de carboestiril
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser
HUP0204511A2 (en) Use of ppar activator or ligand in preparation of pharmaceutical compositions for treatment of bone diseas
Al-Zahrani et al. Clinical manifestations of gastrointestinal diseases in the oral cavity
ATE73449T1 (de) 2-piperazinyl-2-oxo-aethylensubstituierte flavonoid-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammenstellungen.
BR0015172A (pt) Nova combinação compreendendo um agonista adreno receptor de beta 2 (beta 2) e um antagonista receptor de leucotrieno
WO2021142282A1 (en) Compositions and methods for ameliorating pain and reducing fever

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM OS ARTIGOS 8O, 13 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]